Company Overview#
Microt Inc. is a medical device company specializing in ophthalmic treatments. The company focuses on developing safe and reliable therapeutic alternatives for glaucoma, a leading cause of blindness worldwide. By designing precision implants, Microt aims to improve patient outcomes through minimally invasive intraocular pressure regulation.
Technology & Product#
The flagship product is the A-stream Glaucoma Shunt, a minimally invasive glaucoma surgery (MIGS) implant. Manufactured domestically in Korea, the A-stream is a 6mm ultra-small tube made of medical-grade silicone. It features a 100μm inner diameter and a 1mm wing fixation structure. The device works by creating a new drainage pathway for aqueous humor, safely reducing intraocular pressure. Microt has also expanded its portfolio into related eye care spaces, launching the Cleaneol eyelid cleanser and Maxnamin health supplements.
Market & Use Cases#
A-stream targets ophthalmologists and eye clinics performing glaucoma surgeries. As a MIGS/MIBS device, it provides an effective surgical option for patients who do not respond adequately to eye drop medications, offering a safer profile compared to traditional, highly invasive glaucoma drainage surgeries.
Traction & References#
A-stream has demonstrated solid clinical validity and commercial traction. By February 2026, the implant had surpassed 3,000 cumulative sales in Korea and was adopted by over 100 domestic medical institutions(Hankyung). A retrospective study published in Eye (2025) analyzing 49 eyes implanted with A-stream reported a significant reduction in mean intraocular pressure from 26.9±8.3 mmHg to 11.9±3.5 mmHg at six months(PMC). Microt holds necessary medical device manufacturing and sales licenses and collaborates on R&D with institutions such as KAIST, Sungkyunkwan University, and Chungbuk National University.
Collaboration Relevance#
Microt is a strong candidate for commercial distribution partnerships with global ophthalmic device companies looking to expand their MIGS portfolios. It is also well-suited for joint clinical trials and R&D collaborations with international eye centers aiming to validate the efficacy of new glaucoma implants in diverse demographics.